Exploration of Neuroscience
September 24, 2024
Bushra Yasin, Shivani Mehta, George Tewfik et al.
2 citations
Chronic neuropathic pain is a significant public health issue affecting an estimated 1.5 billion individuals worldwide. The mechanisms underlying chronic pain are multifaceted and not fully understood. Chronic pain amplifies specific neural pathways through peripheral and central sensitization triggered by repeated exposure to noxious stimuli, ultimately resulting in physical and emotional...
ACS Omega
September 24, 2024
Ana Y Martínez, Alexis Caballero, Rodrigo Ramírez et al.
Psychedelics are psychoactive substances that produce changes in thoughts and feelings and modifications in perceptions of reality. The most potent psychedelic is also the first semisynthetic hallucinogen (lysergic acid diethylamide). Psychedelics have been investigated for decades because of their potential therapeutic effects in the treatment of neuropsychiatric diseases and also because...
Psychedelics
September 24, 2024
Xi Zhu, Chen Zhang, David J Hellerstein et al.
6 citations
Body dysmorphic disorder (BDD) is a severe psychiatric condition characterized by preoccupation with perceived flaws in one's appearance, which the individual views as defective or ugly. Psilocybin, a serotonin 2A receptor agonist with psychedelic properties, has emerged as a potential therapeutic agent for depression and other psychiatric disorders. This study aimed to identify subacute neural...
Headache: The Journal of Head and Face Pain
September 20, 2024
James Rucker, Sadie Hambleton, Catherine Bird et al.
12 citations
Abstract Background Short‐lasting unilateral neuralgiform headache attacks (SUNHA) are trigeminal autonomic cephalalgias that feature intense and recurrent paroxysms of pain and autonomic symptoms. Many patients are left with debilitating symptoms despite best‐available treatment. Psychedelics, such as the serotonin 2A partial agonist psilocybin, have shown promise in related disorders such as...
Neuroscience & Biobehavioral Reviews
September 20, 2024
Isabel Werle, Leandro J Bertoglio
17 citations
Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address these issues linked to anxiety/stress-related disorders effectively. This review identifies dose ranges associated with specific actions across various psychedelics. We examined psilocybin/psilocin, lysergic acid diethylamide (LSD),...
Anatomy of an Avatar
September 19, 2024
Philip Gerrans
Abstract Users of psychedelic drugs often report that their sense of being a self or ‘I’ distinct from the rest of the world has diminished or altogether dissolved in a phenomenon known as ego dissolution (Nour et al., 2016). This is a case of transient disintegration of the self model caused by actions of serotonin 5HT2A agonists. Psychedelic experience provides a window on the nature of self...
Communications Biology
September 19, 2024
Iván Mindlin, Rubén Herzog, Laouen Belloli et al.
18 citations
Disorders of consciousness (DoC) represent a challenging and complex group of neurological conditions characterised by profound disturbances in consciousness. The current range of treatments for DoC is limited. This has sparked growing interest in developing new treatments, including the use of psychedelic drugs. Nevertheless, clinical investigations and the mechanisms behind them are...
Journal of Psychiatry and Neuroscience
September 19, 2024
Gabriella Gobbi
7 citations
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last few years, a renaissance in the use of psychedelic drugs for mental disorders has occurred in Western society; consequently, a pressing scientific need to elucidate the intricate mechanisms underlying their actions has arisen. Psychedelics mainly...
Journal of Pharmacology and Experimental Therapeutics
September 18, 2024
Candace B Johnson, Donna Walther, Matthew J. Baggott et al.
5 citations
3,4-Methylenedioxymethamphetamine (MDMA) has shown efficacy as a medication adjunct for treating post-traumatic stress disorder (PTSD). However, MDMA is also used in nonmedical contexts that pose risk for cardiovascular and neurologic complications. It is well established that MDMA exerts its effects by stimulating transporter-mediated release of the monoamines 5-hydroxytryptamine (5-HT),...
Brain Behavior and Immunity Integrative
September 14, 2024
Bianca Castro Dos Santos, Ana Kéren Gomes Reis, Ricardo Aparecido Baptista Nucci et al.
1 citation
Neuropathic pain (NP), a debilitating and chronic condition often accompanied by comorbid depression, presents significant therapeutic challenges. While conventional pharmacological treatments, though valuable, usually fall short in addressing their multifaceted nature, the pursuit of innovative solutions has led to the exploration of ayahuasca , a psychedelic brew originating from Amazonian...